Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow declines year over year

Q2 FY2026 financing cash flow of $2K (cash outflow) fell 33.3% year over year, ahead of the -104.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 33.3% from the prior quarter.

Context

  • Financing cash flow amounted to 241.1% of revenue in FY2025.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -104.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2K-33.3% QoQ
Last fiscal yearDec 2025
-$217K-100.7% YoY
LTMJun 2026
-$217K-104.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.3%——
1 year-100.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(217K) USD
Year-over-year change
-100.7%

Financing Cash Flow vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 financing cash flow of $217K is the smallest of the 5 companies compared; the peer median is $68.58M.
  • Its year-over-year change of -104.7% is the 4th highest of 5, against a peer median of -17.1%.
  • Financing cash flow amounts to 0.6% of revenue for ATNM, versus a peer median of 221.8%.
ATNM Competitors Peer median
Financing Cash Flow for ATNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$674.37M -9094.6%+619.6%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$146.24M +21.9%-81.7%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$118.65M +258.7%—221.8%
ANVSAnnovis Bio, Inc.LTM Mar 2026$18.52M -56.0%+19474.8%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$217K -104.7%—0.6%
Peer median (excluding ATNM) $68.58M-17.1%+619.6%221.8%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Depreciation & Amortization524K699K790K811K821K
Deferred Income Tax(1.55M)402K000
Stock-Based Compensation1.69M2.8M3.84M5.29M9.19M
Change in Working Capital1.69M38.17M(3.15M)(932K)(704K)
Accounts Receivables00000
Inventory00000
Accounts Payables1.2M4.6M(2.18M)(387K)(346K)
Other Working Capital495K33.57M(972K)(545K)(358K)
Other Non-Cash Items1.55M(402K)000
Operating Cash Flow(20.87M)8.64M(47.34M)(33.07M)(24.58M)
Capital Expenditures(133K)(366K)(153K)(11K)(104K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(133K)(366K)(153K)(11K)(104K)
Debt Repayment(85K)(49K)(4K)(9K)(10K)
Common Stock Issued35.3M23.16M14.87M29.26M0
Common Stock Repurchased0000(207K)
Dividends Paid00000
Other Financing Activities6K0075K0
Financing Cash Flow35.22M23.11M14.87M29.32M(217K)
Effect of Forex Changes00(11K)06K
Net Change in Cash14.22M31.39M(32.63M)(3.76M)(24.9M)
Free Cash Flow(21M)8.28M(47.49M)(33.08M)(24.68M)

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.